Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Kevin W Song, Meletios A Dimopoulos, Katja C Weisel, Philippe Moreau, Antonio Palumbo, Andrew Belch, Stephen Schey, Pieter Sonneveld, Lars Sternas, Xin Yu, Ramesh Amatya, Mara S Monzini, Mohamed Zaki, Christian Jacques, Jesus San Miguel, Kevin W Song, Meletios A Dimopoulos, Katja C Weisel, Philippe Moreau, Antonio Palumbo, Andrew Belch, Stephen Schey, Pieter Sonneveld, Lars Sternas, Xin Yu, Ramesh Amatya, Mara S Monzini, Mohamed Zaki, Christian Jacques, Jesus San Miguel

No abstract available

Keywords: Pomalidomide; multiple myeloma; quality of life.

Figures

Figure 1.

Trial design. aProgression of disease was independently adjudicated in real time. bHiDEX was chosen as comparator because at the time of trial design it was the standard salvage therapy for heavily pre-treated patients. D: days; HiDEX: high-dose dexamethasone; LoDEX: low-dose dexamethasone; OS: overall survival; PD: progressive disease; POM: pomalidomide; SPM: second primary malignancy.

Figure 2.

Cross-sectional analysis of mean HRQoL score changes from baseline per treatment cycle. *P<0.05 unpaired t-test comparing the two treatment groups from baseline; ‡P<0.05 paired t-test (within group mean change from baseline).

Figure 3.

Repeated measure mixed model score changes from baseline (adjusted means). P values indicate unpaired t-test comparing treatment groups. *Significant P value (P<0.05).